Fig. 5 | Scientific Reports

Fig. 5

From: Prognostic significance and response to immune checkpoint inhibitors of RIPK3, MLKL and necroptosis in non-small cell lung cancer

Fig. 5

The distributions of inflammatory/immune cells infiltration in a specific marker of necroptosis activation (pMLKL) negative and positive groups of NSCLC tissues: Box plots showing the distributions of tumor-infiltrating CD8 + T-cells (A), CD163 + M2 macrophages (B), and FOXp3 + T-cells (C) in a specific marker of necroptosis activation (pMLKL) negative and positive groups. *P-value < 0.05. NSCLC non-small cell lung, LUAD lung adenocarcinoma, LUSC lung squamous cell carcinoma.

Back to article page